$0.98
1.02% today
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US00509G2093
Symbol
ABOS
Sector
Industry

Acumen Pharmaceuticals Inc Stock price

$0.98
-0.23 19.18% 1M
-1.39 58.74% 6M
-0.74 43.15% YTD
-2.86 74.53% 1Y
-3.11 76.09% 3Y
-19.12 95.13% 5Y
-19.12 95.13% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.01 1.02%
ISIN
US00509G2093
Symbol
ABOS
Sector
Industry

Key metrics

Market capitalization $59.85m
Enterprise Value $-82.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.95
P/B ratio (TTM) P/B ratio 0.33
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-114.02m
Free Cash Flow (TTM) Free Cash Flow $-86.23m
Cash position $171.56m
EPS (TTM) EPS $-1.70
P/E forward negative
Short interest 3.97%
Show more

Is Acumen Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Acumen Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Acumen Pharmaceuticals Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Acumen Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Acumen Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.18 0.18
0% 0%
-
-0.18 -0.18
0% 0%
-
- Selling and Administrative Expenses 20 20
8% 8%
-
- Research and Development Expense 94 94
122% 122%
-
-114 -114
87% 87%
-
- Depreciation and Amortization 0.18 0.18
0% 0%
-
EBIT (Operating Income) EBIT -114 -114
86% 86%
-
Net Profit -102 -102
95% 95%
-

In millions USD.

Don't miss a Thing! We will send you all news about Acumen Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Acumen Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
2 days ago
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease
Neutral
Seeking Alpha
8 days ago
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemans...
Neutral
GlobeNewsWire
15 days ago
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday,...
More Acumen Pharmaceuticals Inc News

Company Profile

Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft and Caleb Finch in 1996 and is headquartered in Livermore, CA.

Head office United States
CEO Daniel O'Connell
Employees 61
Founded 1996
Website www.acumenpharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today